Literature DB >> 24105662

Common community-acquired infections and subsequent risk of multiple myeloma: a population-based study.

Charlene M McShane1, Liam J Murray, Eric A Engels, Ola Landgren, Lesley A Anderson.   

Abstract

The role of bacteria and viruses as aetiological agents in the pathogenesis of cancer has been well established for several sites, including a number of haematological malignancies. Less clear is the impact of such exposures on the subsequent development of multiple myeloma (MM). Using the population-based U.S. Surveillance Epidemiology and End Results-Medicare dataset, 15,318 elderly MM and 200,000 controls were identified to investigate the impact of 14 common community-acquired infections and risk of MM. Odds ratios (ORs) and associated 95% confidence intervals (CIs) were adjusted for sex, age and calendar year of selection. The 13-month period prior to diagnosis/selection was excluded. Risk of MM was increased by 5-39% following Medicare claims for eight of the investigated infections. Positive associations were observed for several infections including bronchitis (adjusted OR 1.14, 95% CI 1.09-1.18), sinusitis (OR 1.15, 95% CI 1.10-1.20) pneumonia (OR 1.27, 95% CI 1.21-1.33), herpes zoster (OR 1.39, 95% CI 1.29-1.49) and cystitis (OR 1.09, 95% CI 1.05-1.14). Each of these infections remained significantly elevated following the exclusion of more than 6 years of claims data. Exposure to infectious antigens may therefore play a role in the development of MM. Alternatively, the observed associations may be a manifestation of an underlying immune disturbance present several years prior to MM diagnosis and thereby part of the natural history of disease progression.
© 2013 UICC.

Entities:  

Keywords:  herpes zoster; infections; multiple myeloma; respiratory tract infections

Mesh:

Year:  2013        PMID: 24105662      PMCID: PMC3947153          DOI: 10.1002/ijc.28479

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  44 in total

1.  Leukemia, lymphoma, and multiple myeloma following selected medical conditions.

Authors:  M M Doody; M S Linet; A G Glass; G D Friedman; L M Pottern; J D Boice; J F Fraumeni
Journal:  Cancer Causes Control       Date:  1992-09       Impact factor: 2.506

2.  Infections complicating multiple myeloma and chronic lymphocytic leukemia.

Authors:  J J Twomey
Journal:  Arch Intern Med       Date:  1973-10

3.  14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.

Authors:  H Avet-Loiseau; T Facon; A Daviet; C Godon; M J Rapp; J L Harousseau; B Grosbois; R Bataille
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

Review 4.  Thirty years of Medicare: impact on the covered population.

Authors:  M E Gornick; J L Warren; P W Eggers; J D Lubitz; N De Lew; M H Davis; B S Cooper
Journal:  Health Care Financ Rev       Date:  1996

5.  Pneumococcemia as the presenting feature of multiple myeloma.

Authors:  Daniel B Costa; Byol Shin; Dennis L Cooper
Journal:  Am J Hematol       Date:  2004-11       Impact factor: 10.047

Review 6.  Varicella-zoster virus.

Authors:  A M Arvin
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

7.  The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance.

Authors:  H Gregersen; K M Madsen; H T Sørensen; H C Schønheyder; J S Ibsen; J F Dahlerup
Journal:  Eur J Haematol       Date:  1998-08       Impact factor: 2.997

8.  Potential for cancer related health services research using a linked Medicare-tumor registry database.

Authors:  A L Potosky; G F Riley; J D Lubitz; R M Mentnech; L G Kessler
Journal:  Med Care       Date:  1993-08       Impact factor: 2.983

9.  Multiple myeloma and work in agriculture: results of a case-control study in Forlì, Italy.

Authors:  O Nanni; F Falcini; E Buiatti; L Bucchi; M Naldoni; P Serra; E Scarpi; L Saragoni; D Amadori
Journal:  Cancer Causes Control       Date:  1998-05       Impact factor: 2.506

10.  Medical history and the risk of multiple myeloma.

Authors:  A Gramenzi; I Buttino; B D'Avanzo; E Negri; S Franceschi; C La Vecchia
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

View more
  6 in total

1.  A Tale of Two Immunodeficiencies: A Case of Multiple Myeloma Associated with Profound Immune Defect Mimicking Common Variable Immunodeficiency Syndrome.

Authors:  Leonid L Yavorkovsky; Andrew Hope
Journal:  Perm J       Date:  2019-12-06

Review 2.  'Trained immunity': consequences for lymphoid malignancies.

Authors:  Wendy B C Stevens; Mihai G Netea; Arnon P Kater; Walter J F M van der Velden
Journal:  Haematologica       Date:  2016-11-10       Impact factor: 9.941

3.  Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma.

Authors:  Alba Rodríguez-García; María Linares; María Luz Morales; Sophie Allain-Maillet; Nicolas Mennesson; Ricardo Sanchez; Rafael Alonso; Alejandra Leivas; Alfredo Pérez-Rivilla; Edith Bigot-Corbel; Sylvie Hermouet; Joaquín Martínez-López
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

4.  Editorial: The Role of Microorganisms in Multiple Myeloma.

Authors:  Maria Linares; Sylvie Hermouet
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

5.  A multicountry ecological study of cancer incidence rates in 2008 with respect to various risk-modifying factors.

Authors:  William B Grant
Journal:  Nutrients       Date:  2013-12-27       Impact factor: 5.717

6.  Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management.

Authors:  Ilaria J Chicca; Jennifer L J Heaney; Gulnaz Iqbal; Janet A Dunn; Stella Bowcock; Guy Pratt; Kwee L Yong; Timothy D Planche; Alex Richter; Mark T Drayson
Journal:  Blood Cancer J       Date:  2020-11-04       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.